GMR CAR-T

News alerts, weekly reports and conference planners

Company:

Shinshu University

Drug class:

CD116-targeted CAR-T immunotherapy

‹

›

over3years

Current status and future perspective of CAR T-cell therapy for acute myeloid leukemia (PubMed, Rinsho Ketsueki)

We started a first-in-human clinical trial of GMR CAR T-cells in patients with CD116-positive myeloid neoplasms, particularly AML and juvenile myelomonocytic leukemia, in 2021. CAR T-cells can be a promising and practical treatment option for patients with relapsed/refractory AML.

over 3 years ago

Journal • CAR T-Cell Therapy

CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • NKG2D (killer cell lectin like receptor K1)

GMR CAR-T

over3years

A first-in-human clinical trial of piggyBac transposon-mediated GMR CAR-T cells against CD116-positive acute myeloid leukemia and juvenile myelomonocytic leukemia (PubMed, Rinsho Ketsueki)

Safety tests revealed that the toxicity of GMR CAR-T cells was restricted to normal monocytes. Based on the promising results of the nonclinical study, we started a first-in-human clinical trial of GMR CAR-T cells in patients with CD116-positive AML and JMML in 2021.

over 3 years ago

P1 data • Journal • CAR T-Cell Therapy • IO biomarker

CSF2 (Colony stimulating factor 2)

GMR CAR-T

4years

A Phase I/II Clinical Trial of Piggybac -Modified GMR CAR-T Cell Therapy for CD116 Positive Relapsed/Refractory Myeloid Malignancies (ASH 2021)

The patient will be treated with lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide, followed by CAR-T cell infusion. Conclusion : We herein described the protocol of first-in-human GMR CAR-T cells for relapsed/refractory myeloid malignancies. By employing the optimized CAR vector and production protocol, the safety and efficacy of GMR CAR-T cells will be evaluated in this study.

4 years ago

Clinical • P1/2 data • CAR T-Cell Therapy • IO biomarker

CSF2 (Colony stimulating factor 2)

cyclophosphamide • fludarabine IV • GMR CAR-T